Top

International Journal of Clinical Oncology

Published in:

01-08-2015 | Original Article

Increased levels of sperm protein 17 mRNA and circulating antibodies in periampullary carcinoma patients

Authors: Shivam Singh, Anoop Saraya, Rinu Sharma

Published in: International Journal of Clinical Oncology | Issue 4/2015

Abstract

Background

Present-day diagnostic modalities for detecting periampullary carcinoma are suboptimal, and currently used proven markers lack specificity and sensitivity.

Methods

In order to assess the diagnostic potential of sperm protein 17, a cancer testis antigen, quantitative real-time PCR was performed to evaluate the expression of sperm protein 17 in tissue and sera specimens collected from periampullary carcinoma patients and normal subjects. Additionally, circulating levels of anti-sperm protein 17 antibodies were determined in sera of periampullary carcinoma patients and normal subjects using ELISA.

Results

Aberrant expression of sperm protein 17 was found in 14/15 (93 %) periampullary cancer tissues when compared with distant matched nonmalignant tissues (P = 0.006, Mann–Whitney U test). None of the distant matched nonmalignant tissues showed increased expression of sperm protein 17 mRNA. Area under the curve, sensitivity, and specificity were 0.791, 87, and 73 %, respectively. Increased levels of sperm protein 17 mRNA were demonstrated in sera of periampullary carcinoma patients (P = 0.020, Student’s t test). Circulating levels of anti-sperm protein 17 antibody were found to be significantly elevated in 27/30 (90 %) periampullary carcinoma patients (P < 0.001, Student’s t test). Area under the curve, sensitivity, and specificity were 0.954, 86.7, and 96.3 %, respectively. Only two of the normal subjects (7 %) showed elevated levels of anti-sperm protein 17 antibody.

Conclusion

For the first time, our findings suggest that high levels of sperm protein 17 mRNA as well as increased circulating anti-sperm protein 17 antibodies can be used to distinguish periampullary cancer patients from healthy individuals, highlighting the diagnostic potential of sperm protein 17.

Dorandeu A, Raoul JL, Siriser F et al (1997) Carcinoma of ampulla of vater: prognostic factors after curative surgery: a series of 45 cases. Gut Mar 40(3):350–355CrossRef

Sandblom G, Granroth S, Rasmussen IC (2008) TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci 113(1):57–64PubMedCrossRef

Glimelius B, Hoffman K, Einarsson R et al (1996) Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 35:141–148

Cheng YH, Wong EW, Cheng CY (2011) Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis 1(3):209–220PubMedCentralPubMedCrossRef

Yamasaki N, Richardson RT, O’Rand MG (1995) Expression of rabbit sperm protein Sp17 in COS cells and interaction of recombinant Sp17 with rabbit zona pellucida. Mol Reprod Dev 40:48–55PubMedCrossRef

Dong G, Loukinova E, Smith CW et al (1997) Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. J Cell Biochem Suppl 28–29:90–100PubMedCrossRef

Grizzi F, Chiriva-Internati M, Franceschini B et al (2004) Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem 52:549–554PubMedCrossRef

Wen Y, Richardson RT, Widgren EE et al (2001) Characterization of Sp17: a ubiquitous three-domain protein that binds heparin. Biochem J 357:25–31PubMedCentralPubMedCrossRef

Lacy HM, Sanderson RD (2001) Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparin sulfate-mediated cell-cell adhesion. Blood 98:2160–2165PubMedCrossRef

10.

De Jong A, Buchli R, Robbins D (2002) Characterization of sperm protein 17 in human somatic and neoplastic tissues. Cancer Lett 186:201–209PubMedCrossRef

11.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(t)) method. Methods 25(4):402–408PubMedCrossRef

12.

Lea IA, Adoyo P, O’Rand MG (1997) Autoimmunogenicity of the human sperm protein SP17 in vasectomized men and identification of linear B cell epitopes. Fertil Steril 67:355–361PubMedCrossRef

13.

Gupta G, Sharma R, Chattopadhyay TK et al (2007) Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer 120:1739–1747PubMedCrossRef

14.

Wilentz RE, Geradts J, Maynard R et al (1998) Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58:4740–4744PubMed

15.

Caldas C, Hahn SA, da Costa LT et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32PubMedCrossRef

16.

Park SH, Kim YI, Park YH et al (2000) Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of ampulla of Vater. World J Surg 24:54–59PubMedCrossRef

17.

Chung CH, Wilentz RE, Polak MM et al (1996) Clinical significance of K-ras oncogene activation in ampullary neoplasms. J Clin Pathol 49:460–464PubMedCentralPubMedCrossRef

18.

Grizzi F, Gaetani P, Chiriva-Internati M (2010) Sperm protein 17 is expressed in human nervous system tumours. Clin Dev Immunol 2010:891505

19.

Straughn JM Jr, Shaw DR, Guerrero A et al (2004) Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 108(6):805–811PubMedCrossRef

20.

Arora S, Matta A, Shukla NK et al (2005) Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42(2):97–108PubMedCrossRef

21.

Li FQ, Han YL, Liu Q et al (2009) Overexpression of human sperm protein 17 increases migration and decreases the chemosensitivity of human epithelial ovarian cancer cells. BMC Cancer 9:323PubMedCentralPubMedCrossRef

22.

Bumm K, Grizzi F, Franceschini B et al (2005) Sperm protein 17 expression defines two subsets of primary esthesioneuroblastoma. Hum Pathol 36:1289–1293PubMedCrossRef

23.

Lim SH, Wang Z, Chiriva-Internati M et al (2001) Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 97(5):1508–1510PubMedCrossRef

24.

Liggins AP, Lim SH, Soilleux EJ et al (2010) A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun 10:8PubMedCentralPubMed

25.

Kausar T, Ahsan A, Hasan MD et al (2010) Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer 126:1494–1503PubMed

26.

Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729PubMedCrossRef

27.

Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187:1163–1167PubMedCentralPubMedCrossRef

28.

Adams S, O’Neill DW, Nonaka D et al (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181(1):776–784PubMedCentralPubMedCrossRef

29.

Chiriva-Internati M, Wang Z, Xue Y et al (2001) Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunol 31:2277–2283PubMedCrossRef

30.

Chiriva-Internati M, Wang Z, Salati E et al (2002) Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 100:961–965PubMedCrossRef

31.

Chiriva-Internati M, Wang Z, Salati E et al (2002) Tumor vaccine for ovarian carcinoma targeting sperm protein 17. Cancer 94:2447–2453PubMedCrossRef

Title: Increased levels of sperm protein 17 mRNA and circulating antibodies in periampullary carcinoma patients
Authors: Shivam Singh
Anoop Saraya
Rinu Sharma
Publication date: 01-08-2015
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-014-0762-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2015

Differences in attitude toward adjuvant chemotherapy between colorectal cancer survivors and the medical staff of Japanese hospitals

Transoral robotic surgery in management of oropharyngeal cancers: a preliminary experience at a tertiary cancer centre in India

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study

Current therapeutic strategies for rectal cancer

A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001

Keynote webinar | Spotlight on antibody–drug conjugates in cancer